Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: February 2010
-
By Donald Zuhn — In a letter to the editor published in this week's edition of The New England Journal of Medicine, Dr. David Wheadon, Senior Vice President of the Pharmaceutical Research and Manufacturers of America (PhRMA) Scientific & Regulatory Affairs team, attempts to set the record straight regarding a follow-on biologics (FOB) paper…
-
By Suresh Pillai — Court Denies Bid for Bench Trial in RNAi Patent Suit The U.S. District Court for the District of Massachusetts has denied the bid of defendants Whitehead Institute for Biomedical Research, the University of Massachusetts, and the Massachusetts Institute of Technology to have the merits of their patent dispute with plaintiffs…
-
By Donald Zuhn — Last month, Bill and Melinda Gates kicked off the new decade by announcing that their Foundation will be pledging $10 billion over the next ten years to help research, develop, and deliver vaccines to the world's poorest countries. The announcement came at the World Economic Forum's annual meeting in January.…
-
By Kevin E. Noonan — Last month, the Federal Trade Commission released a report about so-called "pay for delay" arrangements, agreements between branded pharmaceutical companies and generic drug companies that delay entry of generic versions of branded drugs. The FTC's position is clear from the title of the Report: "Pay-for-Delay: How Drug Company Pay-Offs…
-
By Sarah Fendrick — As part of its effort to reduce paperwork, the U.S. Patent and Trademark Office is seeking public comment on its current continuing information collection systems. The first information collection system includes information collected to pay fees for issued patents, to request corrections of errors in issued patents, and to submit…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Genetic Technologies Ltd. v. Beckman Coulter, Inc. et al.3:10-cv-00069; filed February 12, 2010 in the Western District of Wisconsin • Plaintiff: Genetic Technologies Ltd.• Defendants: Beckman Coulter, Inc.; Gen-Probe, Inc.; Interleukin Genetics Inc.; Molecular…
-
By James DeGiulio — Last week, NexBio, Inc. announced the issuance of U.S. Patent No. 7,645,448, entitled "Class of Therapeutic Protein Based Molecules." The '448 patent, issued January 12, 2010, is the company's first issued U.S. patent. The patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®) and methods of treating…
-
February 17-18, 2010 – Biotech & Pharmaceutical Patenting (IIR) – Munich, Germany February 24-25, 2010 – 2nd Expert Forum on ITC Litigation & Enforcement (American Conference Institute) – New York, NY March 1-2, 2010 – 4th Annual Patent Law Institute (Practising Law Institute) – New York, NY March 2-4, 2010 – 6th Annual Biosimilars Conference…
-
Patent Resources Group (PRG) will be holding its next group of Advanced Courses between April 11-17, 2010 in Bonita Springs, Florida. Among the courses being offered are: • ANDA Litigation: Critical Issues and Winning Strategies – April 14 • Fundamental Building Blocks for Creating and Enforcing the FDA Orange Book Listable U.S. Patent – April…
-
By Donald Zuhn — Last week, the Secretary's Advisory Committee on Genetics, Health and Society (SACGHS) issued its long-awaited report on gene patents. While the report, entitled "Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests," indicates that gene patents and licensing practices concerning such patents have not had…
Patent Docs 